Elixie

Company Overview

Snapshot

Founded in October 2019 by Yaron Shoob, Elixie operates with 1–10 employees. The company has raised $2 million across one funding round, focusing on enhancing cannabinoids for neurological disorders. Elixie is currently in the clinical trial stage for its products.

Business overview

Elixie is a clinical-stage biotech company specializing in the enhancement of cannabinoids for the symptomatic relief of neurological disorders. The company leverages NANOLIX, a patented and clinically proven Self-nano emulsifying drug delivery system (SNEDDS), to encapsulate validated active pharmaceutical ingredients. By targeting orphan diseases, Elixie aims to register pharmaceuticals through a relatively short route to market with minimal risks. It operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, with a focus on Medical Cannabis and Drug Delivery, serving B2B2C and B2B business models.

Company Intelligence Q&A

What is Elixie's primary focus?

Elixie is a clinical-stage biotech company focused on enhancing cannabinoids for the symptomatic relief of neurological disorders, utilizing its patented NANOLIX drug delivery system.

When was Elixie founded?

Elixie was founded in October 2019 by Yaron Shoob.

What is NANOLIX?

NANOLIX is Elixie's patented, clinically proven Self-nano emulsifying drug delivery system (SNEDDS), used to encapsulate active pharmaceutical ingredients.

What is Elixie's current product development stage?

Elixie's products are currently in the clinical trial stage. The company aims to register pharmaceuticals through a relatively short route to market by targeting orphan diseases.

Which markets does Elixie target?

Elixie targets geomarkets including the United Kingdom, Australia, Canada, United States, Israel, Europe, and the Americas.